Clinical Trials in Italy

• A study to learn how safe the study drug BAY 2416964 (AhR inhibitor) in combination with the treatment pembrolizumab is, how this combinatio… Ended
  2023-503547-33-00 Phase I (Other) Advanced solid tumors Bayer AG
• Safety and efficacy of NMD670 in ambulatory adult patients with Type 3 spinal muscular atrophy (SYNAPSE-SMA) Ended
  2024-516321-31-00 Phase II Type 3 spinal muscular atrophy NMD Pharma A/S
• Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis Ended
  2023-506046-24-00 Phase II Ulcerative Colitis (UC) Amgen Inc.
• Basimglurant in children, adolescents, and young adults with TSC Ended
  2024-512611-53-00 Phase II Tuberous Sclerosis Complex Noema Pharma AG
• A STUDY TO INVESTIGATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 ADMINISTERED INTRAVITREALLY IN PATIENTS WIT… Ended
  2022-501794-39-00 Phase III Uveitic Macular Edema F. Hoffmann-La Roche AG
• A study to investigate the safety and tolerability of intravenous QEQ278 in patients with advanced solid tumors Ended
  2022-500540-38-00 Phase I Non-small cell lung cancer Oesophageal squamous cell carcino… Novartis Pharma AG
• A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects Wi… Ended
  2022-501618-70-00 Phase I (FiH) BRAF-V600 Mutant Solid Tumors including Melanoma, Non-small … C4 Therapeutics Inc.
• Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP. Ended
  2024-512646-42-00 Phase II Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Immunovant Sciences GmbH
• A Phase 3 Study Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib in Participants with Nonsegmental Vitiligo Ended
  2022-501668-16-00 Phase III NON SEGMENTAL VITILIGO Pfizer Inc.
• A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly… Ended
  2022-500275-31-00 Phase III Haemophilia A Swedish Orphan Biovitrum AB (publ)
• Single-center phase II study on the use of electrochemotherapy in the treatment of Paget's disease and high-grade or initially invasive prec… Ended
  2024-518796-65-00 Phase II patients with newly diagnosed or recurrent high-grade or ini… Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• ARTEMIS: A Phase 3 Study of Ravulizumab to Protect Patients with Chronic Kidney Disease (CKD) from Cardiac Surgery Associated Acute Kidney … Ended
  2022-501802-36-00 Phase III Prevention of cardiac surgery associated acute kidney injury Alexion Pharmaceuticals Inc.
• ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Ended
  2022-500535-36-01 Phase III Moderately to severely active ulcerative colitis Abivax
• A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression. Ended
  2023-508163-74-00 Phase III Major Depressive Disorder Janssen Cilag International
• Double-blind, randomized, monocentric study to evaluate the efficacy and safety of memantine in adolescents with Bipolar Disorder Ended
  2024-516713-21-00 Phase III Bipolar Disorder Ospedale Pediatrico Bambino Gesu
• ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended
  2022-500536-11-01 Phase III Moderately to severely active ulcerative colitis Abivax
• A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hype… Ended
  2022-503022-13-00 Phase III Hypertriglyceridemia, Cardiovascular Diseases, Atheroscleros… Ionis Pharmaceuticals Inc.
• A study to test whether spesolimab helps people with skin disease called Netherton syndrome Ended
  2022-501104-10-00 Phase II/III Netherton syndrome (NS) Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH; Boehr…
• A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus … Ended
  2022-500177-13-00 Phase II Metastatic Colorectal Cancer (mCRC) Gilead Sciences Inc.
• Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors Ended
  2022-500694-14-00 Phase I (FiH) Head and Neck Squamous Cell Cancer Beigene Ltd.
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S… Ended
  2022-501753-36-00 Phase III Hidradenitis Suppurativa Incyte Corp.
• MULTICENTRE, RANDOMISED, DOUBLE-BLIND, VEHICLE AND ACTIVE-CONTROLLED PHASE III STUDY EVALUATING THE EFFICACY AND SAFETY OF KETOTIFEN OPHTHAL… Ended
  2023-503185-23-00 Phase III SEASONAL ALLERGIC CONJUNCTIVITIS Genetic S.p.A.
• This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended
  2023-504869-23-00 Phase III/IV Dermatitis atopic AbbVie Deutschland GmbH & Co. KG
• Phase 2 Study of Encorafenib and Binimetinib Plus Pembrolizumab in Participants With BRAF V600E/K Mutation-Positive Melanoma Who Progressed … Ended
  2023-509471-17-00 Phase II Metastatic or unresectable locally advanced BRAF V600E/K mut… Pfizer Inc.

Showing 3,121–3,144 of 3,689 trials